Multiplex CRISPR/Cas9-based Genome Editing for Correction of Dystrophin Mutations That Cause Duchenne Muscular Dystrophy

Overview

Journal Nat Commun

Specialty Biology

Date 2015 Feb 19

PMID 25692716

Citations 224

Authors

David G Ousterout

Ami M Kabadi

Pratiksha I Thakore

William H Majoros

Timothy E Reddy

Charles A Gersbach

Affiliations

Soon will be listed here.

Abstract

The CRISPR/Cas9 genome-editing platform is a promising technology to correct the genetic basis of hereditary diseases. The versatility, efficiency and multiplexing capabilities of the CRISPR/Cas9 system enable a variety of otherwise challenging gene correction strategies. Here, we use the CRISPR/Cas9 system to restore the expression of the dystrophin gene in cells carrying dystrophin mutations that cause Duchenne muscular dystrophy (DMD). We design single or multiplexed sgRNAs to restore the dystrophin reading frame by targeting the mutational hotspot at exons 45-55 and introducing shifts within exons or deleting one or more exons. Following gene editing in DMD patient myoblasts, dystrophin expression is restored in vitro. Human dystrophin is also detected in vivo after transplantation of genetically corrected patient cells into immunodeficient mice. Importantly, the unique multiplex gene-editing capabilities of the CRISPR/Cas9 system facilitate the generation of a single large deletion that can correct up to 62% of DMD mutations.

Citing Articles

Optimal SpCas9- and SaCas9-mediated gene editing by enhancing gRNA transcript levels through scaffold poly-T tract reduction.

Chey Y, Gierus L, Lushington C, Arudkumar J, B Geiger A, Staker L BMC Genomics. 2025; 26(1):138.

PMID: 39939860 PMC: 11823040. DOI: 10.1186/s12864-025-11317-2.

Engineering structural variants to interrogate genome function.

Koeppel J, Weller J, Vanderstichele T, Parts L Nat Genet. 2024; 56(12):2623-2635.

PMID: 39533047 DOI: 10.1038/s41588-024-01981-7.

Deletion of exons 45 to 55 in the DMD gene: from the therapeutic perspective to the in vitro model.

Poyatos-Garcia J, Soblechero-Martin P, Liquori A, Lopez-Martinez A, Maestre P, Gonzalez-Romero E Skelet Muscle. 2024; 14(1):21.

PMID: 39354597 PMC: 11443720. DOI: 10.1186/s13395-024-00353-3.

Correction of exon 2, exon 2-9 and exons 8-9 duplications in DMD patient myogenic cells by a single CRISPR/Cas9 system.

Lemoine J, Dubois A, Dorval A, Jaber A, Warthi G, Mamchaoui K Sci Rep. 2024; 14(1):21238.

PMID: 39261505 PMC: 11390959. DOI: 10.1038/s41598-024-70075-5.

CRISPR technology in human diseases.

Feng Q, Li Q, Zhou H, Wang Z, Lin C, Jiang Z MedComm (2020). 2024; 5(8):e672.

PMID: 39081515 PMC: 11286548. DOI: 10.1002/mco2.672.

References

Lu Q, Yokota T, Takeda S, Garcia L, Muntoni F, Partridge T . The status of exon skipping as a therapeutic approach to duchenne muscular dystrophy. Mol Ther. 2010; 19(1):9-15. PMC: 3017449. DOI: 10.1038/mt.2010.219. View

Hoffman E, Brown Jr R, Kunkel L . Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell. 1987; 51(6):919-28. DOI: 10.1016/0092-8674(87)90579-4. View

Wang Z, Zhu T, Qiao C, Zhou L, Wang B, Zhang J . Adeno-associated virus serotype 8 efficiently delivers genes to muscle and heart. Nat Biotechnol. 2005; 23(3):321-8. DOI: 10.1038/nbt1073. View

Fu Y, Sander J, Reyon D, Cascio V, Joung J . Improving CRISPR-Cas nuclease specificity using truncated guide RNAs. Nat Biotechnol. 2014; 32(3):279-284. PMC: 3988262. DOI: 10.1038/nbt.2808. View

Cong L, Ran F, Cox D, Lin S, Barretto R, Habib N . Multiplex genome engineering using CRISPR/Cas systems. Science. 2013; 339(6121):819-23. PMC: 3795411. DOI: 10.1126/science.1231143. View

Pattanayak V, Lin S, Guilinger J, Ma E, Doudna J, Liu D . High-throughput profiling of off-target DNA cleavage reveals RNA-programmed Cas9 nuclease specificity. Nat Biotechnol. 2013; 31(9):839-43. PMC: 3782611. DOI: 10.1038/nbt.2673. View

Tebas P, Stein D, Tang W, Frank I, Wang S, Lee G . Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N Engl J Med. 2014; 370(10):901-10. PMC: 4084652. DOI: 10.1056/NEJMoa1300662. View

Ousterout D, Perez-Pinera P, Thakore P, Kabadi A, Brown M, Qin X . Reading frame correction by targeted genome editing restores dystrophin expression in cells from Duchenne muscular dystrophy patients. Mol Ther. 2013; 21(9):1718-26. PMC: 3776627. DOI: 10.1038/mt.2013.111. View

Silva G, Poirot L, Galetto R, Smith J, Montoya G, Duchateau P . Meganucleases and other tools for targeted genome engineering: perspectives and challenges for gene therapy. Curr Gene Ther. 2010; 11(1):11-27. PMC: 3267165. DOI: 10.2174/156652311794520111. View

10.

Guilinger J, Pattanayak V, Reyon D, Tsai S, Sander J, Joung J . Broad specificity profiling of TALENs results in engineered nucleases with improved DNA-cleavage specificity. Nat Methods. 2014; 11(4):429-35. PMC: 4010127. DOI: 10.1038/nmeth.2845. View

11.

Perez-Pinera P, Kocak D, Vockley C, Adler A, Kabadi A, Polstein L . RNA-guided gene activation by CRISPR-Cas9-based transcription factors. Nat Methods. 2013; 10(10):973-6. PMC: 3911785. DOI: 10.1038/nmeth.2600. View

12.

Hou Z, Zhang Y, Propson N, Howden S, Chu L, Sontheimer E . Efficient genome engineering in human pluripotent stem cells using Cas9 from Neisseria meningitidis. Proc Natl Acad Sci U S A. 2013; 110(39):15644-9. PMC: 3785731. DOI: 10.1073/pnas.1313587110. View

13.

Zhao C, Farruggio A, Bjornson C, Chavez C, Geisinger J, Neal T . Recombinase-mediated reprogramming and dystrophin gene addition in mdx mouse induced pluripotent stem cells. PLoS One. 2014; 9(4):e96279. PMC: 4004573. DOI: 10.1371/journal.pone.0096279. View

14.

Cradick T, Fine E, Antico C, Bao G . CRISPR/Cas9 systems targeting β-globin and CCR5 genes have substantial off-target activity. Nucleic Acids Res. 2013; 41(20):9584-92. PMC: 3814385. DOI: 10.1093/nar/gkt714. View

15.

van Putten M, van der Pijl E, Hulsker M, Verhaart I, Nadarajah V, van der Weerd L . Low dystrophin levels in heart can delay heart failure in mdx mice. J Mol Cell Cardiol. 2014; 69:17-23. DOI: 10.1016/j.yjmcc.2014.01.009. View

16.

Mamchaoui K, Trollet C, Bigot A, Negroni E, Chaouch S, Wolff A . Immortalized pathological human myoblasts: towards a universal tool for the study of neuromuscular disorders. Skelet Muscle. 2011; 1:34. PMC: 3235972. DOI: 10.1186/2044-5040-1-34. View

17.

Tedesco F, Dellavalle A, Diaz-Manera J, Messina G, Cossu G . Repairing skeletal muscle: regenerative potential of skeletal muscle stem cells. J Clin Invest. 2010; 120(1):11-9. PMC: 2798695. DOI: 10.1172/JCI40373. View

18.

Wang H, Yang H, Shivalila C, Dawlaty M, Cheng A, Zhang F . One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering. Cell. 2013; 153(4):910-8. PMC: 3969854. DOI: 10.1016/j.cell.2013.04.025. View

19.

Li H, Haurigot V, Doyon Y, Li T, Wong S, Bhagwat A . In vivo genome editing restores haemostasis in a mouse model of haemophilia. Nature. 2011; 475(7355):217-21. PMC: 3152293. DOI: 10.1038/nature10177. View

20.

Sander J, Joung J . CRISPR-Cas systems for editing, regulating and targeting genomes. Nat Biotechnol. 2014; 32(4):347-55. PMC: 4022601. DOI: 10.1038/nbt.2842. View